News
GOSS
1.080
-2.70%
-0.030
WKHS, OPEN and BILI are among pre market gainers
Seeking Alpha · 7h ago
Gossamer Bio (GOSS) Gets a Buy from Wedbush
TipRanks · 2d ago
Analysts Conflicted on These Healthcare Names: Zymeworks (ZYME), Gossamer Bio (GOSS) and Vaccitech Plc (VACC)
TipRanks · 2d ago
Barclays Maintains Equal-Weight on Gossamer Bio, Lowers Price Target to $1.5
Benzinga · 2d ago
--Barclays Adjusts Price Target on Gossamer Bio $1.50 From $2, Keeps Equalweight Rating
--Barclays Adjusts Price Target on Gossamer Bio $1.50 From $2, Keeps Equalweight Rating
MT Newswires · 2d ago
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 3d ago
SVB Securities Sticks to Their Buy Rating for Gossamer Bio (GOSS)
TipRanks · 3d ago
BRIEF-Gossamer Bio Inc Reports Quarterly Loss Per Share Of $0.59
Reuters · 6d ago
Gossamer Bio Q4 EPS $(0.59) Beats $(0.62) Estimate
Benzinga · 6d ago
Gossamer Bio GAAP EPS of -$0.59 beats by $0.03
Seeking Alpha · 6d ago
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 03/16 17:56
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 03/16 17:31
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 03/13 21:32
Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success
Benzinga · 03/07 18:37
Gossamer downgraded at Raymond James after Merck data for PAH candidate
Seeking Alpha · 03/07 17:08
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Benzinga · 03/07 15:00
Raymond James Downgrades Gossamer Bio to Market Perform, Announces $5 Price Target
Benzinga · 03/07 12:12
Raymond James downgrades Gossamer Bio (GOSS) to a Hold
TipRanks · 03/07 11:05
Raymond James Downgrades Gossamer Bio to Market Perform From Outperform
Raymond James Downgrades Gossamer Bio to Market Perform From Outperform
MT Newswires · 03/07 07:56
More
Webull provides a variety of real-time GOSS stock news. You can receive the latest news about Gossamer Bio through multiple platforms. This information may help you make smarter investment decisions.
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).